Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Arndt, Joseph W ^a   Qian, Fang ^a   Smith, Benjamin A ^a   Quan, Chao ^a   Kilambi, Krishna Praneeth ^a   Bush, Martin W ^b   Walz, Thomas ^a,b   Pepinsky, R Blake ^a   Bussière, Thierry ^a   Hamann, Stefan ^a   Cameron, Thomas O ^a   Weinreb, Paul H ^a  

^a BIOGEN   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADUCANUMAB; AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ANTIBODY COMBINING SITE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KINETICS; METABOLISM; MOLECULAR DOCKING; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES, ANTIBODY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOTHERAPY; KINETICS; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE;

EID: 85045873515     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-24501-0     Document Type: Article

References (65)

1. Selkoe, D. J., Abraham, C. R., Podlisny, M. B. & Duffy, L. K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem. 46, 1820-1834 (1986).
2. Bayer, T. & Wirths, O. Focusing the amyloid cascade hypothesis on N-truncated Aβ peptides as drug targets against Alzheimer's disease. Acta Neuropathol. 127, 787-801 (2014).
3. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25years. EMBO Molecular Medicine 8, 595-608 (2016).
4. Polanco, J. C. et al. Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies. Nat Rev Neurol. 14, 22-29 (2018).
5. Mullard, A. Alzheimer amyloid hypothesis lives on. Nat Rev Drug Discov. 16, 3-5 (2016).
6. Budd Haeberlein, S. L. & Harris, T. J. Promising targets for the treatment of neurodegenerative diseases. Clin Pharmacol Ther. 98, 492-501 (2015).
7. van Dyck, C. H. Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and promise. Biological Psychiatry 83, 311-319 (2018).
8. Sevigny, J. et al. Aducanumab removes β-amyloid plaques and slows clinical decline in Alzheimer's disease. Nature 537, 50-56 (2016).
9. Bohrmann, B. et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 28, 49-69, https://doi.org/10.3233/jad-2011-110977 (2012).
10. Bohrmann, B. et al. A comparative study of binding properties of gantenerumab and aducanumab analog to aggregated amyloid-β. Neurodegener Dis. 17(suppl 1), 829 (2017).
11. Lannfelt, L. et al. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther. 6, https://doi.org/10.1186/alzrt246 (2014).
12. Englund, H. et al. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem. 103, 334-345 (2007).
13. Gardberg, A. S. et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA 104, 15659-15664, https://doi.org/10.1073/pnas.0705888104 (2007).
14. Feinberg, H. et al. Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimer's Res Ther. 6, 31 (2014).
15. Watt, A. D. et al. Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? Acta Neuropathologica 127, 803-810, https://doi.org/10.1007/s00401-014-1290-2 (2014).
16. Ultsch, M. et al. Structure of crenezumab complex with Aβ Shows Loss of β-Hairpin. Sci Rep. 6, https://doi.org/10.1038/srep39374 (2016).
17. Adolfsson, O. et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci. 32, 9677-9689, https://doi.org/10.1523/jneurosci.4742-11.2012 (2012).
18. Crespi, G. A. N., Hermans, S. J., Parker, M. W. & Miles, L. A. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. Sci Rep. 5, https://doi.org/10.1038/srep09649 (2015).
19. La Porte, S. L. et al. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Bio. 421, 525-536, https://doi.org/10.1016/j.jmb.2011.11.047 (2012).
20. Jarrett, J. T., Berger, E. P. & Lansbury, P. T. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochem. 32, 4693-4697 (1993).
21. DeMattos, R. B. et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98, 8850-8855 (2001).
22. Miles, L. A., Crespi, G. A., Doughty, L. & Parker, M. W. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-β peptide in a helical conformation. Sci Rep. 3, 1302, https://doi.org/10.1038/srep01302 (2013).
23. Raveh, B., London, N., Zimmerman, L. & Schueler-Furman, O. Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors. PLoS One 6, e18934 (2011).
24. Basi, G. S. et al. Structural correlates of antibodies associated with acute reversal of amyloid β-related behavioral deficits in a mouse model of Alzheimer disease. J Bio Chem. 285, 3417-3427, https://doi.org/10.1074/jbc.M109.045187 (2010).
25. Crespi, G. A., Ascher, D. B., Parker, M. W. & Miles, L. A. Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β. Acta Crystallogr F Struct Biol Commun. 70, 374-377, https://doi.org/10.1107/s2053230x14001642 (2014).
26. Miles, L. A. et al. Amyloid-β-anti-amyloid-β complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol. 377, 181-192, https://doi.org/10.1016/j.jmb.2007.12.036 (2008).
27. Dalgediene, I. et al. Immunogenic properties of amyloid β oligomers. J Biomed Sci. 20, 1-7 (2013).
28. Lee, M. et al. Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann Neurol. 58, 430-435 (2005).
29. Freir, D. B. et al. Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging 32, 2211-2218, https://doi.org/10.1016/j.neurobiolaging.2010.01.001 (2011).
30. Mucke, L. & Selkoe, D. J. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2, https://doi.org/10.1101/cshperspect.a006338 (2012).
31. Reed, M. N. et al. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging 32, 1784-1794, https:// doi.org/10.1016/j.neurobiolaging.2009.11.007 (2011).
32. Giuffrida, M. L. et al. β-amyloid monomers are neuroprotective. J Neurosci. 29, 10582-10587, https://doi.org/10.1523/ jneurosci.1736-09.2009 (2009).
33. Brannstrom, K. et al. A generic method for design of oligomer-specific antibodies. PloS One 9, https://doi.org/10.1371/journal. pone.0090857 (2014).
34. Golde, T. E., Das, P. & Levites, Y. Quantitative and mechanistic studies of Aβ immunotherapy. CNS Neurol Disord Drug Targets 8, 31-49 (2009).
35. Gregory, G. C. & Halliday, G. M. What is the dominant Aβ species in human brain tissue? A review. Neurotox Res. 7, 29-41 (2005).
36. Hu, W. T. et al. CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease? Ann Clin Transl Neurol. 2, 131-139 (2015).
37. Oe, T. et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 20, 3723-3735 (2006).
38. Tucker, S. et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimer's Dis. 43, 575-588, https://doi.org/10.3233/jad-140741 (2015).
39. Benilova, I., Karran, E. & De Strooper, B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 15, 349-357 (2012).
40. Lord, A. et al. An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 36, 425-434 (2009).
41. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
42. Lee, E. B. et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem. 281, 4292-4299 (2006).
43. Morgado, I. et al. Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment. Proc Natl Acad Sci USA 109, 12503-12508 (2012).
44. Shughrue, P. J. et al. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging 2010, 189-202 (2010).
45. Colvin, B. A. et al. The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region. J Neurochem. 143, 736-749 (2017).
46. Hatami, A., Albay, R., Monjazeb, S., Milton, S. & Glabe, C. Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J. Bio. Chem. 289, 32131-32143, https://doi.org/10.1074/ jbc.M114.594846 (2014).
47. Tycko, R. Amyloid polymorphism: structural basis and neurobiological relevance. Neuron 86, 632-645, https://doi.org/10.1016/j. neuron.2015.03.017 (2015).
48. Colvin, M. T. et al. Atomic resolution structure of monomorphic Aβ(42) amyloid fibrils. J Amer Chem Soc. 138, 9663-9674, https:// doi.org/10.1021/jacs.6b05129 (2016).
49. Walti, M. A. et al. Atomic-resolution structure of a disease-relevant Aβ(1-42) amyloid fibril. Proc Natl Acad Sci USA 113, E4976-E4984, https://doi.org/10.1073/pnas.1600749113 (2016).
50. Xiao, Y. L. et al. Aβ(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nat Struct Mol Bio. 22, 499-505, https://doi.org/10.1038/nsmb.2991 (2015).
51. Lu, J. X. et al. Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154, 1257-1268, https://doi. org/10.1016/j.cell.2013.08.035 (2013).
52. Paravastu, A. K., Qahwash, I., Leapman, R. D., Meredith, S. C. & Tycko, R. Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci USA 106, 7443-7448, https://doi.org/10.1073/ pnas.0812033106 (2009).
53. Qiang, W., Yau, W. M., Lu, J. X., Collinge, J. & Tycko, R. Structural variation in amyloid- β fibrils from Alzheimer's disease clinical subtypes. Nature 541, 217-221, https://doi.org/10.1038/nature20814 (2017).
54. Bard, F. et al. Peripherally administered antibodies against amyloid β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 6, 916-919 (2000).
55. Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262-265, https:// doi.org/10.1126/science.1105850 (2005).
56. Lusty, C. J. A gentle vapor-diffusion technique for cross-linking of protein crystals for cryocrystallography. J Appl Cryst. 32, 106-112 (1999).
57. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
58. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 67, 235-242, https:// doi.org/10.1107/S0907444910045749 (2011).
59. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 66, 486-501, https://doi.org/10.1107/S0907444910007493 (2010).
60. Vagin, A. A. et al. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr D Biol Crystallogr. 60, 2184-2195, https://doi.org/10.1107/S0907444904023510 (2004).
61. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J Mol Bio. 372, 774-797, https://doi. org/10.1016/j.jmb.2007.05.022 (2007).
62. Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. J Mol Bio. 234, 946-950 (1993).
63. Leaver-Fay, A. & Al, E. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545-574 (2011).
64. Bradley, P., Misura, K. M. S. & Baker, D. Toward high-resolution de novo structure prediction for small proteins. Science 309, 1868-1871 (2005).
65. Kilambi, K. P., Reddy, K. & Gray, J. J. Protein-protein docking with dynamic residue protonation states. PLoS Comput Biol. 10, e1004018 (2014).